US life sciences damages averaged $33.5m between 2019-2025

Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

Buying the brains: Why is Big Pharma shopping for innovation?

27 July 2026 With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last?

Regulation & Industry

Trump slaps 100% tariff on generic drugs in US manufacturing push

23 July 2026 Generic drug manufacturers face huge penalties if they fail to relocate production to the US within two years, with India among the countries expected to be hardest hit.

Regulation & Industry

UK Prime Minister axes science ministry in govt shakeup

22 July 2026 Plans to merge the UK’s standalone science ministry into an expanded business department, coupled with the departure of the Science Minister, mark a change in the country’s approach to science and innovation.

More features

Buying the brains: Why is Big Pharma shopping for innovation?

FisherBroyles and Hong Kong affiliate draft in senior partners

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

AbbVie, Allergan takes on Swiss aesthetics rival over syringe design

Trump slaps 100% tariff on generic drugs in US manufacturing push

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

UK Prime Minister axes science ministry in govt shakeup

Masimo keeps $634m smartwatch award and moves to appeal

US life sciences damages averaged $33.5m between 2019-2025

More on this story

Editor's picks

Editor's picks

More features